Lundbeck Q3 2019 Financial Results
Lu AF82422: Potential disease modifying antibody in Parkinson's
Pathogenesis of Parkinson's (PD)
Cellular aging
Lewy body
formation
Genetic
mutations
activity
Lu AF82422 is a human IgG1
mAb that recognizes all major
alpha-synuclein forms including
aggregated/misfolded forms
involved in the pathogenesis of
Parkinson's
First single-ascending-dose study
to evaluate safety and
tolerability of Lu AF82422 in
healthy volunteers and
Parkinson's patients
Intervention aimed for delay in
disease progression in PD or
other synucleinopathies
Decreased chaperone
Neuronal
death
Aggregated
misfolded
alpha-syn.
Increased dopamine
oxidation
Defective
processing of
alpha-syn.
Oxidative stress
Mitochondrial
dysfunction
Toxins
Ongoing phase I study1:
*
Healthy non-Japanese and
Japanese subjects and in
patients with Parkinson's
-45 participants
Primary endpoint: Number of
patients with incidence of
Treatment-Emergent Adverse
Events (safety and tolerability)
from dosing to Day 84
Study initiated in July 2018
34
Modified based on Javed et al. CNS & Neurological
Disorders - Drug Targets, 2016, Vol. 15, No. 10
1) NCT03611569
LundbeckView entire presentation